Advertisement
UK markets open in 4 hours 9 minutes

  • NIKKEI 225

    37,780.35
    +151.87 (+0.40%)
     

  • HANG SENG

    17,535.17
    +250.63 (+1.45%)
     

  • CRUDE OIL

    83.85
    +0.28 (+0.34%)
     

  • GOLD FUTURES

    2,346.00
    +3.50 (+0.15%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • Bitcoin GBP

    51,549.40
    +206.89 (+0.40%)
     

  • CMC Crypto 200

    1,391.03
    +8.46 (+0.61%)
     

  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     

  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2022

BBS-Bioactive Bone Substitutes Oyj
·2-min read

BBS-Bioactive Bone Substitutes, Company announcement, 10th December 2021 at 9:40 a.m.

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General Meeting in 2022

During the year 2022, BBS-Bioactive Bone Substitutes Plc (”BBS”) will publish the financial information as follows:

Financial Statements Release for the year 2021 Thursday, 24 February 2022
Half-year financial report January-June 2022 Thursday, 25 August 2022
The Annual Report for the year 2021 will be published during the week 13/2022

The Annual General Meeting is planned to be held on Thursday, 28 April 2022. Company’s Board of Directors Plc will convene the meeting at a later date.

ADVERTISEMENT

BBS-Bioactive Bone Substitutes Oyj

Ilkka Kangasniemi, CEO

More information:
Ilkka Kangasniemi, CEO
tel. +358 40 7080 307
e-mail: ilkka.kangasniemi@bbs-artebone.fi

Certified Advisor: Nordic Certified Adviser AB,+46 70 551 67 29,
info@certifiedadviser.se

DISTRIBUTION:
Nasdaq Helsinki Oy
Nasdaq Stockholm AB
Centric media
www.bbs-artebone.fi

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi. More information: www.bbs-artebone.fi

BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.